Chemokine RANTES is increased at early stages of coronary artery disease

Journal of Physiology and Pharmacology

Volumn 67, Issue 2, 2016, Pages 321-328

  Podolec, Jakub ^a   Kopec, G ^a   Niewiara, L ^a   Komar, M ^a   Guzik, B ^a   Bartus, K ^a   Tomkiewicz Pajak, L ^a   Guzik, T J ^a   Plazak, W ^a   Zmudka, K ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Chemokines; Coronary artery disease; Flow mediated dilatation; Interleukin 18; Intima media thickness; RANTES

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 18; RANTES; BIOLOGICAL MARKER; CCL5 PROTEIN, HUMAN; INTERLEUKIN 18 PROTEIN, HUMAN;

ADULT; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTERIAL WALL THICKNESS; ARTERY DILATATION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RISK FACTOR; BLOOD; BRACHIAL ARTERY; CORONARY ANGIOGRAPHY; CORONARY BLOOD VESSEL; DIAGNOSTIC IMAGING; MIDDLE AGED; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

AGED; BIOMARKERS; BRACHIAL ARTERY; CAROTID INTIMA-MEDIA THICKNESS; CHEMOKINE CCL5; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; FEMALE; HUMANS; INTERLEUKIN-18; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84971539897     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2012; 33: 1635-1701.
2. Podolec P, Kopec G, Pajak A, et al. Polish forum for prevention guidelines on cardiovascular risk assessment. Kardiol Pol 2007; 65: 100-104.
3. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Int J Behav Med 2012; 19: 403-488.
4. Kopec G, Podolec P, Podolec J, Rubis P, Zmudka K, Tracz W. Atherosclerosis progression affects the relationship between endothelial function and aortic stiffness. Atherosclerosis 2009; 204: 250-254.
5. Wilcox JN, Nelken NA, Coughlin SR, Gordon D, Schall TJ. Local expression of inflammatory cytokines in human atherosclerotic plaques. J Atheroscler Thromb 1994; 1 Suppl 1: S10-S13.
6. Reape TJ, Rayner K, Manning CD, et al. Expression and cellular localization of the CC chemokines PARC and ELC in human atherosclerotic plaques. Am J Pathol 1999; 154: 365-374.
7. Hagg DA, Olson FJ, Kjelldahl J, et al. Expression of chemokine (C-C motif) ligand 18 in human macrophages and atherosclerotic plaques. Atherosclerosis 2009; 204: e15-e20.
8. O’Brien AD, Standiford TJ, Christensen PJ, Wilcoxen SE, Paine R. Chemotaxis of alveolar macrophages in response to signals derived from alveolar epithelial cells. J Lab Clin Med 1998; 131: 417-424.
9. de Jager SCA, Bongaerts BWC, Weber M, et al. Chemokines CCL3/MIP1α, CCL5/RANTES and CCL18/PARC are independent risk predictors of short-term mortality in patients with acute coronary syndromes. PLoS One 2012; 7: e45804. doi: 10.1371/journal.pone.0045804
10. Kraaijeveld AO, de Jager SCA, de Jager WJ, et al. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation 2007; 116: 1931-1941.
11. Parissis JT, Adamopoulos S, Venetsanou KF, Mentzikof DG, Karas SM, Kremastinos DT. Serum profiles of C-C chemokines in acute myocardial infarction: possible implication in postinfarction left ventricular remodeling. J Interferon Cytokine Res 2002; 22: 223-229.
12. Montecucco F, Braunersreuther V, Lenglet S, et al. CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice. Eur Heart J 2012; 33: 1964-1974.
13. Braunersreuther V, Steffens S, Arnaud C, et al. A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol 2008; 28: 1090-1096.
14. Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007; 204: 2449-2460.
15. Guzik TJ, Marvar PJ, Czesnikiewicz-Guzik M, Korbut R. Perivascular adipose tissue as a messenger of the brain-vessel axis: role in vascular inflammation and dysfunction. J Physiol Pharmacol 2007; 58: 591-610.
16. Virani SS, Nambi V, Hoogeveen R, et al. Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study. Eur Heart J 2011; 32: 459-468.
17. Cavusoglu E, Eng C, Chopra V, Clark LT, Pinsky DJ, Marmur JD. Low plasma RANTES levels are an independent predictor of cardiac mortality in patients referred for coronary angiography. Arterioscler Thromb Vasc Biol 2007; 27: 929-935.
18. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flowmediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-265.
19. Megnien JL, Simon A, Gariepy J, et al. Preclinical changes of extracoronary arterial structures as indicators of coronary atherosclerosis in men. J Hypertens 1998; 16: 157-163.
20. Bots ML, Grobbee DE, Hofman A, Witteman JCM. Common carotid intima-media thickness and risk of acute myocardial infarction: the role of lumen diameter. Stroke 2005; 36: 762-767.
21. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-369.
22. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
23. Zebrack JS, Muhlestein JB, Horne BD, Anderson JL. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol 2002; 39: 632-637.
24. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999; 99: 2079-2084.
25. Hulthe J, McPheat W, Samnegard A. Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6. Atherosclerosis 2006; 188: 450-454.
26. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351(9096): 88-92.
27. Liu J, Jia Y-J, Li X-L, et al. RANTES gene G-403A polymorphism and coronary artery disease: a meta analysis of observational studies. PLoS One 2012; 7: e47211. doi: 10.1371/journal.pone.0047211.
28. Wang L, Hu X, Zhang S, Xu X, Wang J. Association of the CCR5∆32 polymorphism and its ligand RANTES-403G/A polymorphism with coronary artery disease: a meta-analysis. Thromb Res 2013; 131: e77-e84.
29. Tomaszek A, Kiczak L, Bania J, et al. Increased gene expression of catecholamine-synthesizing enzymes in adrenal glands contributes to high circulating catecholamines in pigs with tachycardia-induced cardiomyopathy. J Physiol Pharmacol 2015; 66: 227-231.
30. Rothenbacher D, Muller-Scholze S, Herder C, Koenig W, Kolb H. Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol 2006; 26: 194-199.
31. + exchanger inhibition and their combination in reducing coronary reperfusion-induced arrhythmias. J Physiol Pharmacol 2015; 66: 215-226.
32. Herder C, Peeters W, Illig T, et al. RANTES/CCL5 and risk for coronary events: results from the MONICA/KORA Augsburg case-cohort, Athero-Express and CARDIoGRAM studies. PLoS One 2011; 6: e25734. doi: 10.1371/journal.pone.0025734.
33. Tribulova N, Egan Benova T, Szeiffova Bacova B, Viczenczova C, Barancik M. New aspects of pathogenesis of atrial fibrillation: remodelling of intercalated discs. J Physiol Pharmacol 2015; 66: 625-634.